Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Correction of postoperative refractive error with Sulcoflex aspheric IOL

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Monofocal/Accommodative

Session Date/Time: Tuesday 13/09/2016 | 16:30-18:00

Paper Time: 16:36

Venue: Hall C2

First Author: : M.Yugay RUSSIA

Co Author(s): :    A. Ryabtseva                    

Abstract Details


In some cases, it is impossible to achieve emmetropic refraction after cataract surgery due to incorrect calculation of IOL power. Pseudophakic 
supplementary IOLs are used to correct refractive error. The purpose of our study was to evaluate the efficacy and safety of Sulcoflex Aspheric IOL for the correction of postoperative refractive error .


Moscow Region Scientific Research Clinical institute, Moscow, Russian Federation


6 patients had myopic refraction from 4 to 6 diopters after cataract surgery. Time after the operation was from 2 to 6 years. In 2 cases the first operation - extracapsular cataract extraction with rigid PMMA IOL implantation, in 4 cases - cataract phacoemulcification with flexible IOL implantation of a hydrophilic (2 cases) and hydrophobic (2 cases) acrylic IOL. Fellow eyes were in all cases emmetropic after phaco. Sulcoflex IOL was implanted in the ciliary sulcus in all cases.


The result was emmetropia with restored binocular vision. Postoperative IOP in all cases was normal, there were no signs of uveitis . In the long run both IOLs mantained transparency, pigment dispersion characteristics were observed (observation period from 6 months to 2 years).


Implantation of Sulcoflex IOL in the ciliary sulcus allows to obtain emmetropic refraction and does not cause complications.

Financial Disclosure:


Back to previous